Christine M. Lovly, Ph.D.
Affiliations: | 2006 | Washington University, Saint Louis, St. Louis, MO |
Area:
Molecular Biology, Cell BiologyGoogle:
"Christine Lovly"Parents
Sign in to add mentor| Helen Piwnica-Worms | grad student | 2006 | Washington University | |
| (DNA damage induced phosphorylation, activation, and ubiquitin-mediated proteolysis of the Chk2 tumor suppressor protein.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sivapalan L, Iams WT, Belcaid Z, et al. (2023) Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF14 |
| Desai A, Lovly CM. (2023) Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. Translational Lung Cancer Research. 12: 615-628 |
| Ettinger DS, Wood DE, Aisner DL, et al. (2023) NCCN GuidelinesĀ® Insights: Non-Small Cell Lung Cancer, Version 2.2023. Journal of the National Comprehensive Cancer Network : Jnccn. 21: 340-350 |
| Lin HM, Wu Y, Yin Y, et al. (2022) Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States. Clinical Lung Cancer |
| Remsing Rix LL, Sumi NJ, Hu Q, et al. (2022) IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Science Signaling. 15: eabj5879 |
| Sato H, Kubota D, Qiao H, et al. (2022) SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors. Jco Precision Oncology. 6: e2200088 |
| Brown BP, Zhang YK, Kim S, et al. (2022) Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 119: e2206588119 |
| Ettinger DS, Wood DE, Aisner DL, et al. (2022) Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 20: 497-530 |
| Ettinger DS, Wood DE, Aisner DL, et al. (2021) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network : Jnccn. 19: 254-266 |
| Du Z, Brown BP, Kim S, et al. (2021) Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. Nature Communications. 12: 1382 |